Jonathan Eckard - 16 Sep 2022 Form 4 Insider Report for TYME TECHNOLOGIES, INC.

Role
Chief Business Officer
Signature
By: /s/ Richard Cunningham as attorney-in-fact for Jonathan Eckard
Issuer symbol
N/A
Transactions as of
16 Sep 2022
Net transactions value
$0
Form type
4
Filing time
16 Sep 2022, 18:00:37 UTC
Previous filing
26 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -500,000 -100% 0 16 Sep 2022 Common Stock 500,000 $4.31 Direct F1
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -150,000 -100% 0 16 Sep 2022 Common Stock 150,000 $2.90 Direct F2
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -150,000 -100% 0 16 Sep 2022 Common Stock 150,000 $2.90 Direct F3
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -370,700 -100% 0 16 Sep 2022 Common Stock 370,700 $1.56 Direct F4
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -300,000 -100% 0 16 Sep 2022 Common Stock 300,000 $1.39 Direct F5
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -431,000 -100% 0 16 Sep 2022 Common Stock 431,000 $1.43 Direct F6
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -482,200 -100% 0 16 Sep 2022 Common Stock 482,200 $0.3200 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Jonathan Eckard is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 21,910 shares of Syros common stock for $98.36 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split").
F2 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 6,573 shares of Syros common stock for $66.18 per share, after giving effect to the Reverse Split.
F3 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 6,573 shares of Syros common stock for $66.18 per share, after giving effect to the Reverse Split.
F4 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 16,244 shares of Syros common stock for $35.60 per share, after giving effect to the Reverse Split.
F5 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 13,146 shares of Syros common stock for $31.72 per share, after giving effect to the Reverse Split.
F6 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 18,886 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.
F7 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,130 shares of Syros common stock for $7.30 per share, after giving effect to the Reverse Split.